Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
QuintilesIMS
Moodys
Citi
Cerilliant
Cantor Fitzgerald
McKesson
AstraZeneca
Baxter
US Army

Generated: August 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,368,460 protect, and when does it expire?


Patent ► Subscribe protects SELZENTRY and is included in two NDAs. There has been one Paragraph IV challenge on Selzentry.

This patent has ninety-one patent family members in fifty-five countries.

Summary for Patent: ► Subscribe

Title:Tropane derivatives useful in therapy
Abstract:The present invention provides compounds of the formula: ##STR00001## wherein R.sup.1 is C.sub.3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C.sub.1-6 alkyl optionally substituted by one or more fluorine atoms, or C.sub.3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R.sup.2 is phenyl optionally substituted by one or more fluorine atoms, to pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.
Inventor(s): Perros; Manoussos (Sandwich, GB), Price; David Anthony (Sandwich, GB), Stammen; Blanda Luzia Christa (Sandwich, GB), Wood; Anthony (Sandwich, GB)
Assignee: Pfizer, Inc. (New York, NY)
Application Number:10/678,836
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-003Nov 4, 2016RXYesNo► Subscribe► Subscribe METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-004Nov 4, 2016RXYesNo► Subscribe► Subscribe METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-001Aug 6, 2007RXYesNo► Subscribe► Subscribe METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-002Aug 6, 2007RXYesYes► Subscribe► Subscribe METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
Viiv Hlthcare
SELZENTRY
maraviroc
SOLUTION;ORAL208984-001Nov 4, 2016RXYesYes► Subscribe► Subscribe METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0014046.7May 26, 2000
United Kingdom0015835.2Jun 27, 2000

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,667,314 Tropane derivatives useful in therapy► Subscribe
7,576,097Tropane derivatives useful in therapy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Yugoslavia82202► Subscribe
Portugal1526134► Subscribe
Portugal1284974► Subscribe
Poland200551► Subscribe
Poland359267► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Covington
Fuji
Julphar
UBS
McKinsey
Dow
Chinese Patent Office
McKesson
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot